| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1021088288 |
| P356 | DOI | 10.1007/S11926-003-0023-7 |
| P698 | PubMed publication ID | 12967519 |
| P50 | author | Michelle A. Petri | Q67485110 |
| P2860 | cites work | Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men | Q72369034 |
| The management of thrombosis in the antiphospholipid-antibody syndrome | Q72619159 | ||
| Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients | Q74284472 | ||
| Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus | Q78609890 | ||
| High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin | Q28185196 | ||
| A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke | Q28192128 | ||
| Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis | Q28192594 | ||
| Warfarin, aspirin, or both after myocardial infarction | Q28193836 | ||
| Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients | Q33369688 | ||
| A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. | Q33504515 | ||
| Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment | Q33565796 | ||
| Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism | Q34179254 | ||
| Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. | Q40279074 | ||
| The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. | Q40903111 | ||
| Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. | Q41109148 | ||
| Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice | Q41927420 | ||
| Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators | Q43681404 | ||
| Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis | Q48394757 | ||
| A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism | Q49171054 | ||
| Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. | Q53354829 | ||
| The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. | Q53361537 | ||
| A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. | Q53374794 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| thrombosis | Q261327 | ||
| P304 | page(s) | 370-3 | |
| P577 | publication date | 2003-10-01 | |
| P1433 | published in | Current Rheumatology Reports | Q23930052 |
| P1476 | title | Evidence-based management of thrombosis in the antiphospholipid antibody syndrome | |
| P478 | volume | 5 |
| Q43901099 | Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients |
| Q28222458 | Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up |
| Q33630290 | Complement system on the attack in autoimmunity |
| Q37141852 | High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study |
| Q33692770 | Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety |
| Q35940099 | Treatment of the antiphospholipid antibody syndrome |
| Q84600032 | [Antiphospholipid syndrome treatment, to whom, when and how long?] |
Search more.